<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The hallmark of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is the t(14;18)(q32;q21) chromosomal translocations that lead to deregulation of BCL2 expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>However, not <z:hpo ids='HP_0000001'>all</z:hpo> cases of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> express BCL2, nor is the t(14;18) translocation always present </plain></SENT>
<SENT sid="2" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> lacking the BCL2 rearrangement are less well studied with regards to their immunohistochemical and molecular features </plain></SENT>
<SENT sid="3" pm="."><plain>This study aims to investigate the BCL2 protein expression pattern in t(14;18) negative follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: BCL2 protein expression pattern was analysed in 26 cases of t(14;18) negative follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> [determined by fluorescence in situ hybridisation (FISH)], using antibodies against two-different <z:chebi fb="0" ids="53000">epitopes</z:chebi>, i.e., the widely-used antibody BCL2/124 and an alternative antibody E17 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Two of the t(14;18) negative cases showed evidence of BCL2 amplification and <z:mp ids='MP_0004027'>trisomy</z:mp> 18 </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 13 cases (50%) lacked BCL2 expression </plain></SENT>
<SENT sid="7" pm="."><plain>In 10 cases (38%) the expression was <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> and in only three cases (12%) the BCL2 expression was strongly positive </plain></SENT>
<SENT sid="8" pm="."><plain>These cases could thus be subdivided into three subgroups: Group I, <z:mpath ids='MPATH_458'>normal</z:mpath> BCL2 genes (i.e., no evidence of translocation or amplification), and BCL2 protein negative; Group II, <z:mpath ids='MPATH_458'>normal</z:mpath> BCL2 genes but BCL2 protein positive; and Group III, presence of other genetic alterations, i.e., BCL2 amplification and <z:mp ids='MP_0004027'>trisomy</z:mp> 18, and BCL2 protein positive </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: This study suggests that it may be possible on the basis of staining to predict that the t(14;18) translocation is absent if a case is either negative for BCL2 protein with different antibodies or has <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> BCL2 expression, possibly acquired through a physiological process of differentiation </plain></SENT>
</text></document>